{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:26Z","timestamp":1793042666921,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.nucmedbio.2024.108943","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:06:49Z","timestamp":1722046009000},"page":"108943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["[89Zr]ZrCl4 for direct radiolabeling of DOTA-based precursors"],"prefix":"10.1016","volume":"136-137","author":[{"given":"Serge K.","family":"Lyashchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Happel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hijin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio V.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NagaVaraKishore","family":"Pillarsetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108943_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41181-024-00258-y","article-title":"Good practices for 89Zr radiopharmaceutical production and quality control","volume":"9","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108943_bb0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.119.239558","article-title":"The role of 89Zr-Immuno-PET in navigating and derisking the development of biopharmaceuticals","volume":"62","author":"van Dongen","year":"2021","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108943_bb0015","first-page":"1271","article-title":"89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies","volume":"44","author":"Verel","year":"2003","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2024.108943_bb0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","article-title":"Standardized methods for the production of high specific-activity zirconium-89","volume":"36","author":"Holland","year":"2009","journal-title":"Nucl Med Biol"},{"issue":"26","key":"10.1016\/j.nucmedbio.2024.108943_bb0025","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1039\/C4DT00733F","article-title":"Charting the mechanism and reactivity of zirconium oxalate with hydroxamate ligands using density functional theory: implications in new chelate design","volume":"43","author":"Holland","year":"2014","journal-title":"Dalton Trans"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108943_bb0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2967\/jnumed.118.216457","article-title":"89Zr-chloride can be used for Immuno-PET radiochemistry without loss of antigen reactivity in vivo","volume":"60","author":"Pandya","year":"2019","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108943_bb0035","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/molecules24081534","article-title":"Preparation of Zirconium-89 solutions for radiopharmaceutical purposes: interrelation between formulation, radiochemical purity, stability and biodistribution","volume":"24","author":"Larenkov","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108943_bb0040","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1039\/C6SC04128K","article-title":"Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development","volume":"8","author":"Pandya","year":"2017","journal-title":"Chem Sci"},{"key":"10.1016\/j.nucmedbio.2024.108943_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nucmedbio.2021.12.003","article-title":"Radiolabeling of PSMA-617 with 89Zr: a novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results","volume":"106-107","author":"Imura","year":"2022","journal-title":"Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108943_bb0050","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","article-title":"89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man","volume":"49","author":"Priv\u00e9","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.nucmedbio.2024.108943_bb0055","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s00259-023-06241-0","article-title":"Detection efficacy of [89Zr]Zr-PSMA-617 PET\/CT in [68Ga]Ga-PSMA-11 PET\/CT-negative biochemical recurrence of prostate cancer","volume":"50","author":"Rosar","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108943_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2018.06.003","article-title":"Evaluation of a chloride-based 89Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin","volume":"64\u201365","author":"Graves","year":"2018","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108943_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.apradiso.2016.09.024","article-title":"A simple and convenient method for production of 89Zr with high purity","volume":"118","author":"Tang","year":"2016","journal-title":"Appl Radiat Isot"},{"issue":"13","key":"10.1016\/j.nucmedbio.2024.108943_bb0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jlcr.4003","article-title":"The impact of zirconium-89 solution formulation on the efficiency of [89Zr]Zr-deferoxamine synthesis","volume":"65","author":"Bubenshchikov","year":"2022","journal-title":"J Labelled Comp Radiopharm"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108943_bb0075","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","article-title":"A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals","volume":"48","author":"Kalidindi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108943_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.nucmedbio.2024.108943_bb0085","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108943_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J Appl Toxicol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108943_bb0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2174\/157340611796799186","article-title":"89Zr radiochemistry for positron emission tomography","volume":"7","author":"Severin","year":"2011","journal-title":"Med Chem"},{"issue":"7","key":"10.1016\/j.nucmedbio.2024.108943_bb0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108943_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"European Federation of Pharmaceutical Industries Association and European Centre for the validation of alternative methods. A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J Appl Toxicol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:06:04Z","timestamp":1727298364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"alternative-id":["S0969805124000696"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108943","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[89Zr]ZrCl4 for direct radiolabeling of DOTA-based precursors","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108943"}}